MLTX
HEALTHCAREMoonLake Immunotherapeutics
What's Moving MLTX Today?
No stock-specific AI insight has been generated for MLTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$21.22
Fundamentals
Trading
MLTX News
21 articles- MoonLake Immunotherapeutics (NASDAQ: MLTX) seeks $150M via offeringStock Titan·Jun 22, 2026
- MLTX Stock Clocks Best Day In Over 6 Months — What’s Driving The Investor Optimism?Stocktwits·Jun 22, 2026
- MoonLake Immunotherapeutics Announces Proposed Public OfferingYahoo Finance·Jun 22, 2026
- Why Is MLTX Stock Rallying Nearly 20% Overnight?Stocktwits·Jun 22, 2026
- MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026Yahoo Finance·Jun 21, 2026
- MLTX Stock Moves Higher As Traders Position For Late-Stage Trial CatalystsStocktwits·Jun 17, 2026
- Why Did MLTX Stock Rise After-Hours Today?Stocktwits·Jun 9, 2026
- MoonLake Immunotherapeutics CFO Trims His Stake. Should Investors Be Concerned?Motley Fool·Jun 5, 2026
- MoonLake Immunotherapeutics (MLTX) Price Target Raised to $45 At H.C. Wainwright on FDA ProgressYahoo Finance·Jun 2, 2026
- MoonLake Immunotherapeutics (MLTX) Is Up 7.3% After FDA Aligns on Sonelokimab BLA PathwayYahoo Finance·May 12, 2026
- MoonLake Clears A Key Regulatory Hurdle, And Shares RocketYahoo Finance·May 11, 2026
- MoonLake (MLTX) Shares Gain After Positive FDA Meeting on Sonelokimab FilingAdvfn·May 11, 2026
- Update: MoonLake Immunotherapeutics Q1 Net Loss WidensYahoo Finance·May 11, 2026
- MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial ResultsYahoo Finance·May 10, 2026
- Avalo shares spike on skin drug data; BioNTech to cut staffBiopharmadive·May 6, 2026
- The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?The Motley Fool·Apr 18, 2026
- Biotech Fund BVF Trims MoonLake Stake, Sells $63M in SharesThe Motley Fool·Apr 7, 2026
- How Investors Are Reacting To MoonLake Immunotherapeutics (MLTX) Long-Term Sonelokimab Data In Hidradenitis SuppurativaYahoo Finance·Apr 5, 2026
- MoonLake’s lead asset shows durability in late-stage HS studiesClinicaltrialsarena·Mar 31, 2026
- MoonLake Trial Data Continue to Support Efficacy of Sonelokimab to Treat Hidradenitis Suppurativa, Wedbush SaysYahoo Finance·Mar 30, 2026
- MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual MeetingGlobeNewswire Inc.·Mar 28, 2026
All 21 articles loaded
Price Data
52-Week Range
$21.22
Fundamentals
Trading
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a pioneering biotechnology company focused on the development of advanced therapies for chronic inflammatory diseases, utilizing its proprietary drug delivery technology. The firm is currently progressing its lead candidate, a novel interleukin-17 inhibitor, through multiple phases of clinical trials, which could significantly reshape treatment approaches and enhance patient outcomes. With a strong research pipeline and strategic partnerships, MoonLake Immunotherapeutics is well-positioned to address substantial unmet medical needs in the immunotherapy landscape, offering considerable investment potential.